TED Ted Baker Plc

RNS Number:0210H
Tepnel Life Sciences PLC
01 August 2006







1st August 2006





              Tepnel Life Sciences PLC ('Tepnel' or 'the Company')


                                   Trading Update



Tepnel (AIM: TED), the UK-based international Molecular Diagnostics and Research
Products & Services group, is pleased to announce the following trading update
for the first half of 2006.

Tepnel's results for the 6 months ended 30 June 2006 will reflect continued
strong top line sales growth and a better than budgeted bottom line.  Sales for
the first half of the year were #8.16m (unaudited) compared to #6.89m
(unaudited) for the same period in 2005, indicating 18.4% sales growth.  The
Molecular Diagnostics group recorded sales of #4.69m (2005: #4.01m) while
Research Products & Services reported sales of #3.47m (2005: #2.88m). These much
improved sales resulted in operating profit significantly ahead of previous
forecasts when combined with improved margins and cost control. The overall
result for the first half of 2006 will show an operating profit before
exceptional items of #45,000 compared to an operating loss of #391,000 for the
same period in 2005.

Ben Matzilevich, CEO, stated "Our strategy has been to identify significant
molecular diagnostic and research product niche market opportunities and to take
leadership positions in these sectors.

We are especially gratified to see that sales of our genomic products and
services have more than doubled in the first half of this year compared to the
same period last year.  Molecular Diagnostic reagents for organ transplantation
monitoring (bone marrow, kidney, liver, heart, etc.) have increased sales by 40%
from the same period.  These are two important markets where we have invested
resources and focused our energies and we are now seeing the benefits of those
efforts with sales and profit growth.

In all sectors we are competing with large global players and we have chosen to
compete by targeting superior products into selected regional markets focusing
on highly specialized applications backed up by strong technical support.  Our
new facilities in Scotland, where we are due to commence construction this
month, will give us the laboratories we need to maintain our growth and expand
our genomic and proteomic product lines.

We believe that close attention to the bottom line and expanded sales and
marketing efforts into the USA plus our strong product pipeline will help
position Tepnel for continued growth and improved profitability."


About Tepnel

Tepnel Life Sciences (TLS) is a UK based international biotechnology company.
The Company has laboratories, manufacturing and operations in the USA, UK and
France with 195 employees.  TLS provides test kits, reagents and services to two
highly synergistic markets, these being Molecular Diagnostics and Biomedical
Research.  The company's strategy has been to identify high growth niche
opportunities within these multi-billion pound markets.  TLS focuses on these
niche opportunities with internally developed products, patents, expertise and
know-how as well as strategic acquisitions, to develop a leadership position
within these defined market segments.




Enquiries:


Ben Matzilevich, Chief Executive Officer, Tepnel Life Sciences plc 0161 946 2200
Mark Percy, Seymour Pierce Limited                                 0207 107 8000
Richard Anderson, De Facto Communications Ltd                      0207 861 3838



Seymour Pierce Limited ("Seymour Pierce"), which is regulated in the United
Kingdom by the Financial Services Authority, is acting for Tepnel in relation to
the matters described in this announcement and is not advising any other person,
and accordingly will not be responsible to anyone other than Tepnel for
providing the protections afforded to customers of Seymour Pierce or for
providing advice in relation to the matters described in this announcement.



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

TSTFGGFNNMRGVZM

Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024

Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024